Entropy Technologies LP Acquires 119,453 Shares of Bristol Myers Squibb Company $BMY

Entropy Technologies LP boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 83.1% in the 4th quarter, HoldingsChannel reports. The firm owned 263,144 shares of the biopharmaceutical company’s stock after purchasing an additional 119,453 shares during the quarter. Bristol Myers Squibb makes up approximately 0.8% of Entropy Technologies LP’s portfolio, making the stock its 23rd largest holding. Entropy Technologies LP’s holdings in Bristol Myers Squibb were worth $14,194,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BMY. Brighton Jones LLC boosted its stake in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC boosted its stake in Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after purchasing an additional 2,786 shares during the period. United Bank raised its holdings in shares of Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after acquiring an additional 3,277 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $221,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $405,000. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst commentary highlighted that BMY’s growth portfolio now generates more than half of revenue, with Reblozyl, Breyanzi and Cobenfy delivering strong gains that help balance declines in legacy products. Article Title
• Positive Sentiment: Bristol Myers Squibb advanced its Phase 1 liver study for BMS-986435, adding another pipeline update that supports long-term growth prospects. Article Title
• Positive Sentiment: The company also reported momentum in its mavacamten heart-drug franchise, with a real-world study signaling continued traction in the cardiovascular market. Article Title
• Neutral Sentiment: Bristol Myers is rolling out an AI-driven procurement overhaul and expanding an oncology collaboration with Arcus Biosciences, which could improve efficiency and bolster its cancer pipeline over time. Article Title
• Neutral Sentiment: Erste Group made only small tweaks to earnings estimates, leaving FY2026 in line with consensus and slightly trimming FY2027, a mixed signal that does not materially change the near-term outlook. Article Title
• Negative Sentiment: Takeda said its AI-designed psoriasis pill beat Bristol Myers’ Sotyktu in a head-to-head trial, raising competitive concerns for one of BMY’s dermatology assets. Article Title

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on BMY. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Barclays began coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective on the stock. HSBC upped their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $57.05 on Friday. The stock’s fifty day moving average is $57.73 and its 200 day moving average is $56.87. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm has a market capitalization of $116.49 billion, a PE ratio of 16.02, a PEG ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter in the prior year, the firm posted $1.80 EPS. Bristol Myers Squibb’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.32 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares in the company, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.